Biotech Catalyst Calendar 2026: Every FDA Decision Date That Moves Stocks
A biotech catalyst calendar is a structured view of upcoming FDA decision dates, advisory committee votes, clinical trial readouts, and regulatory milestones that can move biotech stocks significantly. This guide explains how catalysts work and how to track them using BiotechSign's real-time calendar.
What Is a Biotech Catalyst?
A biotech catalyst is any regulatory or clinical event with a predictable date that has the potential to significantly move a company's stock price. The most important catalysts are binary events — outcomes that are clearly positive or negative with little middle ground. FDA approval decisions, Phase 3 trial results, and adcom vote outcomes are the three primary catalyst types that biotech investors track on a calendar.
PDUFA Dates: The Primary Catalyst
PDUFA dates are the FDA's deadlines to approve or reject new drug applications. They're set when the FDA accepts a drug application for review — typically 6-10 months before the decision date. For investors, PDUFA dates are the highest-value calendar entries because the timing is known far in advance, the binary outcome is clear, and the price impact can be extreme (often 50-300% moves). BiotechSign's PDUFA calendar tracks every upcoming decision date with drug name, indication, and application type.
FDA Advisory Committee Meetings
Before many major PDUFA decisions, the FDA convenes an advisory committee (adcom) of independent experts to vote on approval recommendation. Adcom meetings typically occur 1-3 months before the PDUFA date. The committee vote is non-binding but highly predictive — the FDA follows the adcom recommendation about 80% of the time. A strong adcom vote creates a pre-PDUFA rally opportunity; a negative vote can crash the stock before the official FDA decision. BiotechSign's adcom calendar includes historical vote records for context.
Phase 3 Trial Readouts
Companies announce Phase 3 clinical trial results through press releases and 8-K SEC filings. Unlike PDUFA dates set by the FDA, trial readout timing is disclosed by the company — often in quarterly earnings calls, SEC filings, and investor presentations. These dates can shift, so tracking them requires monitoring multiple sources. BiotechSign aggregates announced readout windows and updates them as companies provide guidance.
How to Use a Biotech Catalyst Calendar
Effective catalyst calendar use involves more than knowing the date. Evaluate the setup: Is the drug first-in-class or facing competition? What do Phase 2 data suggest about Phase 3 probability? Have insiders been buying? Is there unusual current short-interest activity? The date is the anchor — the supporting signals determine whether the risk/reward is favorable. BiotechSign surfaces converging signals around calendar events to help identify the source-backed setups.
Building a Watchlist from the Catalyst Calendar
Start with BiotechSign's PDUFA calendar filtered to the next 90 days. Identify companies with meaningful catalysts in the near term. Cross-reference against the signals screen: insider buying, adcom history, orphan drug designation. Prioritize setups where multiple positive signals converge around a defined catalyst date. This process is what institutional biotech investors call 'event-driven screening.'
BiotechSign tracks FDA catalysts, PDUFA dates, adcom meetings, and biotech signals for 8,000+ companies in real time.
Open BiotechSign →